[go: up one dir, main page]

MX2010003036A - Composicion farmaceutica de liberacion controlada ph dependiente para no opioides con resistencia a la influencia del etanol. - Google Patents

Composicion farmaceutica de liberacion controlada ph dependiente para no opioides con resistencia a la influencia del etanol.

Info

Publication number
MX2010003036A
MX2010003036A MX2010003036A MX2010003036A MX2010003036A MX 2010003036 A MX2010003036 A MX 2010003036A MX 2010003036 A MX2010003036 A MX 2010003036A MX 2010003036 A MX2010003036 A MX 2010003036A MX 2010003036 A MX2010003036 A MX 2010003036A
Authority
MX
Mexico
Prior art keywords
weight
pharmaceutical composition
opioids
controlled release
polymer mixture
Prior art date
Application number
MX2010003036A
Other languages
English (en)
Inventor
Hans-Ulrich Petereit
Hema Ravishankar
Ashwini Samel
Original Assignee
Evonik R Hm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik R Hm Gmbh filed Critical Evonik R Hm Gmbh
Publication of MX2010003036A publication Critical patent/MX2010003036A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/501Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invenci?n le interesa trata sobre una composici?n farmac?utica de liberaci?n controlada pH dependiente, que consta de al menos un ingrediente activo farmac?utico, con la excepci?n de opioides, en donde el n?cleo se encuentra revestido al menos por una capa de revestimiento, que controle la liberaci?n de composici?n farmac?utica, en donde la capa de revestimiento est? compuesta por una mezcla polim?rica de i) 40 - 95% por peso, con base en el peso en seco de la mezcla polim?rica, de al menos un pol?mero o copol?mero de vinilo esencialmente neutral e insoluble en agua, y ii) 5 - 60% por peso, con base en el peso en seco de la mezcla polim?rica, de al menos un pol?mero o copol?mero ani?nico, que es insoluble en un medio amortiguado por debajo de un pH de 4.0 y soluble al menos en un rango de pH de 7.0 a 8.0. que se caracteriza porque la capa de revestimiento adem?s contiene 110 a 250% por peso, calculado en el peso en seco de la mezcla polim?rica, de un lubricante inerte no poroso y el revestimiento se encuentra presente en una cantidad de al menos 60% por peso calculado en el peso del n?cleo.
MX2010003036A 2007-09-21 2007-09-25 Composicion farmaceutica de liberacion controlada ph dependiente para no opioides con resistencia a la influencia del etanol. MX2010003036A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2136CH2007 2007-09-21
PCT/EP2007/060130 WO2009036811A1 (en) 2007-09-21 2007-09-25 Ph-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol

Publications (1)

Publication Number Publication Date
MX2010003036A true MX2010003036A (es) 2010-04-09

Family

ID=39278276

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003036A MX2010003036A (es) 2007-09-21 2007-09-25 Composicion farmaceutica de liberacion controlada ph dependiente para no opioides con resistencia a la influencia del etanol.

Country Status (13)

Country Link
US (1) US9555006B2 (es)
EP (1) EP2187875B1 (es)
JP (1) JP5204846B2 (es)
KR (1) KR101454056B1 (es)
CN (1) CN101801356B (es)
BR (1) BRPI0722042B8 (es)
CA (1) CA2699224C (es)
ES (1) ES2393805T3 (es)
IL (1) IL203870A (es)
MX (1) MX2010003036A (es)
PL (1) PL2187875T3 (es)
SI (1) SI2187875T1 (es)
WO (1) WO2009036811A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5965583B2 (ja) 2007-08-13 2016-08-10 インスピリオン デリバリー テクノロジーズ エルエルシー 乱用抵抗性医薬組成物、その使用方法および作製方法
PL2326313T3 (pl) 2008-09-24 2015-08-31 Evonik Roehm Gmbh Kompozycja farmaceutyczna o zależnym od pH kontrolowanym uwalnianiu dla nieopioidów z odpornością przed wpływem etanolu
CN102164588B (zh) * 2008-09-24 2015-07-08 赢创罗姆有限公司 耐受乙醇影响的pH依赖性受控释放的药物组合物
WO2010057869A1 (en) * 2008-11-18 2010-05-27 Ucb Pharma, S.A. Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate
AU2009317280B2 (en) 2008-11-18 2014-03-06 Ucb Pharma, S.A. Prolonged release formulations comprising an 2 -oxo- 1 -pyrrolidine derivative
CN102355893A (zh) 2009-03-18 2012-02-15 赢创罗姆有限公司 采用含有中性乙烯基聚合物和赋形剂的包衣的具有耐乙醇影响的控释药物组合物
CA2994873A1 (en) 2009-12-02 2011-06-09 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US9877925B2 (en) 2010-05-14 2018-01-30 Ethypharm Alcohol-resistant oral pharmaceutical form
US20130059010A1 (en) * 2010-05-14 2013-03-07 Ethypharm Alcohol-resistant oral pharmaceutical form
BR112013027484A8 (pt) * 2011-06-17 2022-07-05 Evonik Roehm Gmbh Composição farmacêutica ou nutracêutica com resistência gástrica, e uso de um polímero de (met)acrilato
US9844511B2 (en) * 2011-06-17 2017-12-19 Evonik Roehm Gmbh Coating composition suitable for pharmaceutical or nutraceutical dosage forms
US9668977B2 (en) 2011-06-17 2017-06-06 Evonik Röhm Gmbh Coating composition suitable for pharmaceutical or nutraceutical dosage forms
CA2900781A1 (en) * 2013-02-13 2014-08-21 Evonik Rohm Gmbh Multiparticulate pharmaceutical composition comprising a multitude of two kinds of pellets
US20140275150A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US20150352140A1 (en) * 2014-06-07 2015-12-10 Api Intellectual Property Holdings, Llc Biomass-based dietary supplement
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
CN105769823A (zh) * 2014-12-24 2016-07-20 上海星泰医药科技有限公司 一种左旋盐酸米那普仑缓释胶囊及其制备方法
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
MX2020002790A (es) 2017-09-14 2020-08-20 Evonik Operations Gmbh Polimero y forma de dosis con propiedades de liberacion sostenida y resistencia contra la influencia de etanol.
EP3485879A1 (en) * 2017-11-17 2019-05-22 Maat Pharma Pharmaceutical oral formulation comrpsing bacteria
WO2019170485A1 (en) 2018-03-09 2019-09-12 Evonik Röhm Gmbh Polymer mixture with resistance against the influence of ethanol
JP2025508982A (ja) * 2022-03-03 2025-04-10 サイプルメド ゲーエムベーハー 治療用ペプチドおよびタンパク質の改善された経口医薬製剤
IL320492A (en) 2022-10-25 2025-06-01 Veradermics Incorporated Compositions and methods of use for modified release minoxidil

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08143476A (ja) * 1994-11-18 1996-06-04 Japan Tobacco Inc 薬物放出制御膜及び固形製剤
FR2759293B1 (fr) * 1997-02-11 1999-04-30 Ethypharm Lab Prod Ethiques Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
CA2459976A1 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
DE10211289A1 (de) * 2002-03-14 2003-09-25 Basf Ag Kombination von Polyvinylacetat von wasserunlöslichen, säureunlöslichen oder alkaliunlöslichen Polymeren zur Hestellung von Filmüberzügen mit sehr kontrollierter Freisetzung und hoher Stabilität
WO2003086353A1 (en) * 2002-04-05 2003-10-23 Penwest Pharmaceuticals Co. Sustained release metoprolol formulations
AU2004285284B2 (en) * 2003-10-31 2010-03-25 Hexal Ag A process for the preparation of an active-ingredient-containing formulation with a coating
BRPI0606339A2 (pt) * 2005-01-28 2009-06-16 Euro Celtique Sa formas farmacêuticas resistentes a álcool
DE102005024614A1 (de) * 2005-05-25 2006-11-30 Röhm Gmbh Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug

Also Published As

Publication number Publication date
PL2187875T3 (pl) 2013-01-31
CN101801356A (zh) 2010-08-11
IL203870A (en) 2015-02-26
EP2187875B1 (en) 2012-09-05
BRPI0722042A2 (pt) 2014-03-25
EP2187875A1 (en) 2010-05-26
SI2187875T1 (sl) 2012-12-31
WO2009036811A1 (en) 2009-03-26
BRPI0722042B1 (pt) 2019-12-10
CN101801356B (zh) 2016-10-19
KR20100063067A (ko) 2010-06-10
US20100221324A1 (en) 2010-09-02
US9555006B2 (en) 2017-01-31
CA2699224A1 (en) 2009-03-26
KR101454056B1 (ko) 2014-10-27
ES2393805T3 (es) 2012-12-28
JP2010539196A (ja) 2010-12-16
CA2699224C (en) 2014-12-16
BRPI0722042B8 (pt) 2022-07-05
JP5204846B2 (ja) 2013-06-05

Similar Documents

Publication Publication Date Title
MX2010003036A (es) Composicion farmaceutica de liberacion controlada ph dependiente para no opioides con resistencia a la influencia del etanol.
MX2010003032A (es) Composicion farmaceutica opioide de liberacion controlada ph dependiente con resistencia contra la influencia del etanol.
BRPI0823128B8 (pt) composição farmacêutica de liberação controlada dependente do ph para não opioides com resistência contra a influência de etanol, e processo para sua preparação
BRPI0823096B8 (pt) composição farmacêutica de opióide de liberação controlada, dependente do ph, com resistência contra a influência do etanol, processo para sua preparação, e seu uso
MX2011009667A (es) Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante el uso de un revestimiento compuesto de polímeros de vinilo neutrales y excipientes.
MX2011009669A (es) Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes.
WO2007070649A3 (en) Antimicrobial coating system
WO2007006353A3 (de) Verwendung eines teilneutralisierten, anionischen (meth) acrylat-copolymers als uberzug fur die herstellung einer arzneiform mit einer wirkstofffreisetzung bei erniedrigten ph-werten
MX339671B (es) Forma oral solida con perfil de liberacion dual que contiene particulas multiples.
WO2009031295A1 (ja) 薬剤徐放性ステント
WO2009113703A3 (en) Orally-disintegrating solid preparation
WO2009028495A1 (ja) 真菌性皮膚炎用剤
WO2010125323A8 (en) Biocidal composition
BRPI0907194A2 (pt) Composição de revestimento, e, uso de copolímero
EP2664595A3 (en) Plasticizer-containing hardening accelerator composition
WO2009074520A3 (de) Copolymer und ophthalmologische zusammensetzung
WO2012085043A3 (en) Rapidly disintegrating, solid coated dosage form
RU2014101227A (ru) Композиция покрытия, подходящая для фармацевтических или нутрицевтических лекарственных форм
HRP20201880T1 (hr) Transdermalni terapijski sustav namijenjen primjeni aktivne tvari
MX356579B (es) Composicion farmaceutica o nutraceutica de resistencia gastrica con resistencia contra la influenza de etanol.
WO2009057980A3 (en) Photochromic compositions and photochromic films
MX376383B (es) Composicion farmaceutica o nutraceutica con resistencia contra la influencia del etanol
BRPI0810335A2 (pt) "pó depolímero redispersável, dispersão aquosa, composição de polímero e uso da composição de polímero"
WO2008071407A3 (de) Beschichtete pellets
TW200616922A (en) Use of vinyl chloride-ethylene copolymers for imparting water repellency to construction materials

Legal Events

Date Code Title Description
FG Grant or registration